National Pension Service Trims Position in IQVIA Holdings Inc. $IQV

National Pension Service cut its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 275,097 shares of the medical research company’s stock after selling 11,992 shares during the quarter. National Pension Service’s holdings in IQVIA were worth $62,010,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IQV. Ameliora Wealth Management Ltd. purchased a new stake in shares of IQVIA in the fourth quarter worth $25,000. Physician Wealth Advisors Inc. increased its stake in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth $27,000. Westside Investment Management Inc. increased its stake in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA in the third quarter worth $30,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IQV. Citigroup cut their target price on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, April 19th. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. cut their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $225.69.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $182.03 on Friday. IQVIA Holdings Inc. has a 52 week low of $136.41 and a 52 week high of $247.04. The stock has a market capitalization of $30.38 billion, a P/E ratio of 22.56, a PEG ratio of 1.74 and a beta of 1.18. The firm has a fifty day simple moving average of $170.34 and a two-hundred day simple moving average of $196.18. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the company posted $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a share repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.